Structural and kinetic analysis of two covalent sialosyl-enzyme intermediates on Trypanosoma rangeli sialidase

被引:76
作者
Watts, AG
Oppezzo, P
Withers, SG
Alzari, PM
Buschiazzo, A
机构
[1] Inst Pasteur, Unite Biochim Struct, F-75724 Paris 15, France
[2] Inst Pasteur, CNRS, URA 2185, F-75724 Paris 15, France
[3] Univ British Columbia, Dept Chem, Vancouver, BC V6T 121, Canada
关键词
D O I
10.1074/jbc.M510677200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Trypanosoma rangeli sialidase is a glycoside hydrolase ( family GH33) that catalyzes the cleavage of alpha-2 -> 3-linked sialic acid residues from sialoglycoconjugates with overall retention of anomeric configuration. Retaining glycosidases usually operate through a ping-pong mechanism, wherein a covalent intermediate is formed between the carbohydrate and an active site carboxylic acid of the enzyme. Sialidases, instead, appear to use a tyrosine as the catalytic nucleophile, leaving the possibility of an essentially different catalytic mechanism. Indeed, a direct nucleophilic role for a tyrosine was shown for the homologous trans- sialidase from Trypanosoma cruzi, although itself not a typical sialidase. Here we present the three-dimensional structures of the covalent glycosyl-enzyme complexes formed by the T. rangeli sialidase with two different mechanism-based inactivators at 1.9 and 1.7 A resolution. To our knowledge, these are the first reported structures of enzymatically competent covalent intermediates for a strictly hydrolytic sialidase. Kinetic analyses have been carried out on the formation and turnover of both intermediates, showing that structural modifications to these inactivators can be used to modify the lifetimes of covalent intermediates. These results provide further evidence that all siali-dases likely operate through a similar mechanism involving the transient formation of a covalently sialylated enzyme. Furthermore, we believe that the ability to "tune" the inactivation and reactivation rates of mechanism- based inactivators toward specific enzymes represents an important step toward developing this class of inactivators into therapeutically useful compounds.
引用
收藏
页码:4149 / 4155
页数:7
相关论文
共 33 条
[1]
The high resolution structures of free and inhibitor-bound Trypanosoma rangeli sialidase and its comparison with T-cruzi trans-sialidase [J].
Amaya, MF ;
Buschiazzo, A ;
Nguyen, T ;
Alzari, PM .
JOURNAL OF MOLECULAR BIOLOGY, 2003, 325 (04) :773-784
[2]
Structural insights into the catalytic mechanism of Trypanosoma cruzi trans-sialidase [J].
Amaya, MF ;
Watts, AG ;
Damager, I ;
Wehenkel, A ;
Nguyen, T ;
Buschiazzo, A ;
Paris, G ;
Frasch, AC ;
Withers, SG ;
Alzari, PM .
STRUCTURE, 2004, 12 (05) :775-784
[3]
THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[4]
Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? [J].
Brooks, MJ ;
Sasadeusz, JJ ;
Tannock, GA .
CURRENT OPINION IN PULMONARY MEDICINE, 2004, 10 (03) :197-203
[5]
FREE R-VALUE - A NOVEL STATISTICAL QUANTITY FOR ASSESSING THE ACCURACY OF CRYSTAL-STRUCTURES [J].
BRUNGER, AT .
NATURE, 1992, 355 (6359) :472-475
[6]
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[7]
The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis [J].
Buschiazzo, A ;
Amaya, MF ;
Cremona, ML ;
Frasch, AC ;
Alzari, PM .
MOLECULAR CELL, 2002, 10 (04) :757-768
[8]
Antiviral drugs in current clinical use [J].
De Clercq, E .
JOURNAL OF CLINICAL VIROLOGY, 2004, 30 (02) :115-133
[9]
Zanamivir and oseltamivir: Two new options for the treatment and prevention of influenza [J].
Dreitlein, WB ;
Maratos, J ;
Brocavich, J .
CLINICAL THERAPEUTICS, 2001, 23 (03) :327-355
[10]
Polysialylated neural cell adhesion molecule is necessary for selective targeting of regenerating motor neurons [J].
Franz, CK ;
Rutishauser, U ;
Rafuse, VF .
JOURNAL OF NEUROSCIENCE, 2005, 25 (08) :2081-2091